Answers are grounded in this paper and cite their sources.
This paper details important approaches for integrating clinical considerations, nonmeasurable disease and advanced imaging into the treatment planning workflow for TTFields. As TTFields become integrated into standard care pathways for glioblastoma, this case series demonstrates that treatment planning beyond the extent of contrast enhancement is clinically feasible and should be prospectively compared to standard treatment planning in a clinical trial setting, in order to determine the impact on patient outcomes.
No takes yet. Share an insight, caveat, or question.
Connelly et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: